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Introduction {#sec1}
============

γδ T cells make rapid non-redundant contributions in numerous disease settings that include malaria ([@bib2]) and tuberculosis infections ([@bib14]), as well as immunopathologies such as psoriasis ([@bib16]). In addition, γδ T cells display potent anti-tumor capabilities, such that a tumor-associated γδ T cell expression signature was the most favorable immune-related positive prognostic indicator in analyses of more than 18,000 tumors ([@bib7]).

Murine γδ T cells execute their effector capacities through provision of cytokines ([@bib22]). Anti-tumor function is associated with IFNγ production ([@bib6]), whereas IL-17A drives γδ T cell responses to extracellular bacteria and fungi ([@bib4], [@bib12]). This delivery of IFNγ or IL-17A mirrors that of αβ T helper cell clones that acquire cytokine-secreting functions only at the point of peripheral activation in secondary lymphoid tissue. By contrast, γδ T cells largely acquire their effector potential (to secrete IFNγ or IL-17A) in the thymus, well before their participation in subsequent immune responses ([@bib25]).

The mechanisms that drive thymic commitment to γδ T cell effector function are still unclear. "Strong" ligand-dependent signaling through the γδ T cell receptor (TCRγδ) was suggested to promote commitment to an IFNγ-secreting fate ([@bib13], [@bib21], [@bib28]), with weaker, possibly ligand-independent TCR signaling being required for IL-17A production ([@bib13], [@bib28]). However, recent studies have also implicated "strong" TCRγδ signals in commitment to an IL-17A-secreting fate ([@bib3], [@bib29]). Alternatively, evidence exists for TCR-independent commitment to effector potentials. For example, IL-17A-secreting γδ T cells develop exclusively in a perinatal window, such that adoptive transfer of adult bone marrow will not reconstitute the IL-17A-secreting γδ T cell compartment ([@bib10]). IL-17A-producing γδ T cells are also suggested to preferentially develop from CD4^−^CD8^−^ double-negative (DN) 2 cells (rather than DN3 cells) ([@bib27]). And certain γδ T cell subsets (e.g., those using a TCRγ chain incorporating variable region 4; Vγ4^+^ cells) may inherently require certain transcription factors (e.g., Sox-13) ([@bib8], [@bib19]). Clearly, a better understanding of γδ T cell development is required that will provide critical insight into γδ T cell biology.

There is presently no accepted approach for stage-wise assessment of thymic γδ T cell development. Indeed, although studies have analyzed Vγ usage ([@bib8], [@bib28]), acquisition of effector potential ([@bib13], [@bib17], [@bib25], [@bib28]), gene transcription ([@bib26]), and surface marker expression ([@bib3], [@bib9], [@bib13], [@bib17], [@bib25], [@bib28]), a methodology that combines these parameters, akin to that for αβ T cells, is still lacking. Here, using precursor/product relationships, we identify thymic stages in two distinct developmental pathways that generate γδ T cells committed to subsequent secretion of IL-17A or IFNγ. This exposes a temporal disconnect between thymic commitment to effector fate and immediate capacity to display effector function. Cytokine-independent identification of fate-committed γδ T cells reveals the full contribution of Vγ-chain-expressing progenitors to both cytokine-producing pathways through ontogeny, highlighting sizable numbers of IL-17A-committed cells expressing Vγ1 and Vγ2/3 chains. Importantly, these analyses also permit definitive assessment of TCRγδ signal strength in commitment to γδ T cell effector fate; increased TCRγδ signal strength profoundly prohibits the development of all IL-17A-secreting γδ T cells, regardless of Vγ usage but promoted the development of γδ progenitors along the IFNγ pathway. These observations provide important insights into functional γδ T cell biology.

Results {#sec2}
=======

CD24, CD44, and CD45RB Identify Functionally Distinct γδ T Cell Subsets {#sec2.1}
-----------------------------------------------------------------------

There is no consensus for describing stages in murine γδ T cell development. Thus, we re-assessed, on perinatal, neonatal, and post-natal thymic γδ T cells, the expression of γδ T cell surface markers ([@bib3], [@bib9], [@bib13], [@bib25], [@bib29]) combined with intracellular (i.c.) staining for IFNγ and IL-17A ([Figure S1](#mmc1){ref-type="supplementary-material"}). This revealed that staining for CD24, CD44, and CD45RB neatly segregated both thymic ([Figure 1](#fig1){ref-type="fig"}A) and peripheral ([Figure 1](#fig1){ref-type="fig"}B) γδ T cells, throughout ontogeny ([Figure S2](#mmc1){ref-type="supplementary-material"}A), into two apparent "pathways"; CD24^−^ cells that expressed high CD44 but not CD45RB were committed to IL-17A secretion, but did not make IFNγ, whereas cells that had upregulated CD45RB had potential to secrete IFNγ but not IL-17A ([Figures 1](#fig1){ref-type="fig"}A and 1B). CD45RB^hi^ γδ T cells can also upregulate CD44, which correlates with NK1.1 and CD122 expression and robust peripheral commitment to IFNγ secretion ([Figure 1](#fig1){ref-type="fig"}C). Consistent with IL-17A-secreting potential ([@bib20], [@bib25], [@bib26]), CD44^hi^CD45RB^−^ γδ T cells were RORγt^+^T-bet^lo^ ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}B) and expressed significant CD127 (the IL-7Rα chain) that appeared to follow upregulation of CD44 ([Figure 1](#fig1){ref-type="fig"}E). By contrast, CD44^+^CD45RB^+^ γδ cells were T-bet^+^RORγt^lo^ and displayed little CD127 ([Figures 1](#fig1){ref-type="fig"}D, 1E, and [S2](#mmc1){ref-type="supplementary-material"}B). Finally, although we could not detect IL-4-secreting γδ T cells directly ex vivo, a small fraction of the CD44^+^CD45RB^+^ subset from both post-natal thymus and adult spleen produced IL-4 after 18 hr culture in PMA/ionomycin ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Thus, in the thymus and periphery, CD24, CD44, and CD45RB neatly segregate γδ T cells into subsets with IL-17A- or IFNγ-secreting potential.Figure 1CD24, CD44, and CD45RB Identify Functionally Distinct γδ T Cell Subsets(A and B) γδ T cells from (E17) thymic lobes (A) or adult lymph nodes (LNs) (B). For both, CD24^−^ γδ T cells (TCRδ^+^CD3ε^+^) from top left are sub-divided by CD44 and CD45RB (top right; subsets a--d). Middle and bottom plots show intracellular (i.c.) staining for IL-17A/IFNγ in subsets a--d.(C) CD44^−^CD45RB^+^ b (orange) and CD44^+^CD45RB^+^ c (green) γδ T cells from LNs overlaid to show CD122/NK1.1 (left) and i.c. IFNγ (right).(D) Summary of T-bet/IFNγ (top) or RORγt/IL-17A (bottom) in CD44^−^CD45RB^−^, CD44^+^CD45RB^+^, and CD44^hi^CD45RB^−^ thymic γδ T cells through ontogeny. For cytokines, cells were stimulated 4 hr ex vivo with PMA/ionomycin.(E) CD127 on CD45RB^−^ (middle) and CD45RB^+^ (right) thymic γδ T cells from neonatal mice.Data are representative of at least two independent experiments (A--C and E; n ≥ 6 mice), and (D; n ≥ 4 mice or ≥4 lobes pooled for E17). Summarized data are represented as mean ± SD. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

γδ T Cell Commitment to Cytokine-Secreting Potential Follows One of Two Pathways {#sec2.2}
--------------------------------------------------------------------------------

CD44 and CD45RB appear to segregate CD24^−^ γδ T cells into two developmental pathways, whereby CD44^−^CD45RB^−^ cells develop as either CD44^hi^CD45RB^−^ IL-17A-committed γδ T cells or CD45RB^+^ IFNγ-committed γδ T cells. To formally investigate this hypothesis, we used fetal thymic organ culture (FTOC) that re-capitulates thymic T cell development in vitro and is suited to studying γδ T cell development that occurs predominantly in the perinatal period. Indeed, E15 thymic lobes cultured for 7 days generate γδ T cell subsets similar to those observed ex vivo ([Figure 2](#fig2){ref-type="fig"}A). To show precursor/product relationships, we first took E14 lobes and cultured them in FTOC for either 1 or 2 days. Ex vivo, γδ T cells from E14 lobes are all CD24^+^, with a sizable proportion also CD25^+^ ([Figure 2](#fig2){ref-type="fig"}B). Consistent with CD25^+^ γδ T cells' being the earliest γδ T cell subset in the thymus ([@bib23], [@bib25]), the proportion of these cells is notably reduced over a 2-day culture period. On day 1, CD24^+^CD25^−^ cells were the dominate subset, whereas by day 2, a substantial proportion of cells became CD24^−^; this suggests a developmental progression from CD25^+^CD24^+^ to CD25^−^CD24^+^ to CD25^−^CD24^−^.Figure 2γδ T Cell Commitment to Cytokine-Secreting Potential Follows One of Two Pathways(A) Left shows CD44/CD45RB on CD24^−^ γδ T cells from E15 lobes after 7-day FTOC. Right shows i.c. IL-17A/IFNγ in subsets a--d.(B) CD25/CD24 on γδ T cells from E14 lobes ex vivo (left plot) or after 1- or 2-day FTOC (right plots). Summary data are shown to right of plots.(C) Cells sorted from E15 7-day FTOC; a--d (left plot), with post-sort re-runs. Sorted cells from 5-day OP9-DL1 cultures were then stained for CD44/CD45RB and i.c. IL-17A/IFNγ.(D) Summary of (C) showing recovered cells (output) after 5-day culture of sorted cells (input).Data are representative of at least two independent experiments. Summarized data are represented as mean ± SD.

We next fluorescence-activated cell sorting (FACS)-purified the four CD24^−^ γδ T cell populations from 7-day FTOC of E15 thymic lobes. These were CD44^−^CD45RB^−^ a cells, CD44^−^CD45RB^+^ b cells, CD44^+^CD45RB^+^ c cells, and CD44^hi^CD45RB^−^ d cells ([Figure 2](#fig2){ref-type="fig"}C). Sorted cells were then cultured for a further 5 days on OP9-DL1 stromal cells, which also support thymic T cell development, and subsequently re-assessed. On re-analysis, both CD44^+^CD45RB^+^ and CD44^hi^CD45RB^−^ subsets displayed characteristics of terminally differentiated cells, retaining both their CD44/CD45RB expression and complete and full commitment to IFNγ- and IL-17A-secreting potential, respectively ([Figures 2](#fig2){ref-type="fig"}C and 2D). In contrast, the CD44^−^CD45RB^−^ subset differentiated to all other phenotypes, with their CD45RB^+^ products displaying expected IFNγ-secreting potential and their CD44^hi^CD45RB^−^ products appearing committed to IL-17A. Finally, CD44^−^CD45RB^+^ cells gave rise to a significant number of CD44^+^CD45RB^+^ products ([Figures 2](#fig2){ref-type="fig"}C and 2D), suggesting a developmental pathway from CD44^−^CD45RB^−^ to CD44^−^CD45RB^+^ to CD44^+^CD45RB^+^ for an IFNγ-secreting fate. Thus, CD24, CD44, and CD45RB identify two distinct γδ T cell development pathways that segregate commitment to either IFNγ- or IL-17A-secreting potential.

Vγ5^+^ and Vγ6^+^ Cells Fully Segregate to One of the Two Developmental Pathways {#sec2.3}
--------------------------------------------------------------------------------

The preferential use of γδTCRs that incorporate certain Vγ-regions has been frequently correlated with peripheral cytokine-secreting potential: Vγ4^+^ and Vγ6^+^ cells being linked to IL-17A production, with Vγ1^+^ and Vγ5^+^ cells linked to IFNγ ([@bib24]). However, this is difficult to study in the early thymus, as only a minority of neonatal CD24^−^ γδ T cells display immediate cytokine-secreting capacity after 4 hr stimulation with PMA/ionomycin ([Figure S3](#mmc1){ref-type="supplementary-material"}A). In contrast, the vast majority of these CD24^−^ cells have already entered one of the two developmental pathways described above ([Figure 1](#fig1){ref-type="fig"}A) and are thus already committed to a cytokine-secreting fate ([Figure 2](#fig2){ref-type="fig"}C). To use this extra sensitivity to observe cytokine-committed TCRγδ^+^ thymocytes, we assessed through ontogeny, from E17 to day 8 post-birth, Vγ usage of γδ T cells committed to either the IL-17A or IFNγ pathway using staining strategies that detect Vγ1^+^, Vγ2/3^+^, Vγ4^+^, Vγ5^+^, Vγ6^+^, and Vγ7^+^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Before birth, Vγ5^+^ and Vγ6^+^ cells dominated the IFNγ-committed and IL-17A-committed pathways, respectively ([Figure 3](#fig3){ref-type="fig"}A). Indeed, at E17 almost complete segregation of Vγ5^+^ cells to a CD45RB^+^ fate and Vγ6^+^ cells to a CD44^hi^CD45RB^−^ fate was observed ([Figure 3](#fig3){ref-type="fig"}B), which corresponded to T-bet (but not RORγt) expression in Vγ5^+^ cells and RORγt (but not T-bet) expression in Vγ6^+^ cells ([Figure 3](#fig3){ref-type="fig"}C). However, such precise mapping of Vγ staining to one of the two pathways was not observed for other Vγ regions, as Vγ1^+^, Vγ2/3^+^, and Vγ4^+^ cells were clearly represented in both routes of development ([Figures 3](#fig3){ref-type="fig"}A and 3B). Indeed, Vγ2/3^+^ cells, which have been overlooked in murine γδ T cell studies to date, make sizable contributions to both pathways and are as capable as either Vγ4^+^ or Vγ6^+^ (or Vγ1^+^) cells of making IL-17A ([Figure 3](#fig3){ref-type="fig"}D). Finally, Vγ7^+^ cells, which are readily identifiable in early CD24^+^ subsets, are barely detected in either of the mature CD24^−^ pathways ([Figure 3](#fig3){ref-type="fig"}A), supporting the view that these cells leave the thymus at an early stage of thymic development to seed the murine intestine ([@bib5]).Figure 3Vγ5^+^ and Vγ6^+^ Cells Segregate to One of Two Developmental Pathways(A) Vγ usage by CD24^+^, CD44^−^CD45RB^−^, CD44^+^CD45RB^+^, and CD44^hi^CD45RB^−^ thymic γδ T cells through ontogeny.(B) CD44/CD45RB on Vγ5^+^ (green) and Vγ6^+^ (17D1^+^ purple) cells (top) and Vγ1^+^ (blue) and Vγ4^+^ (red) cells (bottom) within CD24^+^ (left) or CD24^−^ (right) subsets from WT thymus.(C) i.c. RORγt/T-bet in Vγ5^+^ and Vγ6^+^ cells within CD24^−^ γδ pool of E17 thymus.(D) i.c. IL-17A/IFNγ in thymic Vγ-chain-specific CD44^hi^CD45RB^−^ γδ T cells through ontogeny.Data are representative of at least two (A--C) or one (D) independent experiments. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Increased TCRγδ Signal Strength Restricts Development of All IL-17A-Secreting γδ T Cells {#sec2.4}
----------------------------------------------------------------------------------------

The factors that dictate commitment to an IL-17A- or IFNγ-secreting fate are still unclear. Central to this is the role of TCRγδ signaling, as although consensus suggests that "strong" TCRγδ signals favor development of IFNγ-committed cells ([@bib13], [@bib21], [@bib28]), conflicting views exist as to the strength of TCRγδ signal required for an IL-17A-secreting fate ([@bib3], [@bib13], [@bib28], [@bib29]). In 7-day FTOC of E15 thymic lobes, addition of anti-TCRγδ antibody GL3, which increases TCRγδ signal strength ([@bib15], [@bib28]), clearly reduced the generation of IL-17A-committed cells while significantly increasing the number of CD44^+^CD45RB^+^ cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). The effect on those cells capable of immediate IL-17A secretion was particularly dramatic, reducing both absolute cell number and the amount of IL-17A produced per cell ([Figure 4](#fig4){ref-type="fig"}C). This effect was GL3 dose dependent ([Figure S4](#mmc1){ref-type="supplementary-material"}A), was not the result of TCR signaling-induced apoptosis ([Figure S4](#mmc1){ref-type="supplementary-material"}B), and resulted in a complete absence of all Vγ-expressing cells in the IL-17A pathway if GL3 was added to 7- to 14-day FTOC of E14 thymic lobes ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Moreover, intraperitoneal administration to pregnant wild-type (WT) mice at 13-days post-conception of the anti-CD3ε antibody 2C11, which induces similar developmental changes as GL3 in vitro ([Figure S4](#mmc1){ref-type="supplementary-material"}D), also resulted in profound reduction of IL-17A-commited γδ T cells in pups at day 2 after birth ([Figure 4](#fig4){ref-type="fig"}D). Finally, and consistent with these findings, cells from the IFNγ pathway, from either 7-day FTOC or day 2 pups ex vivo, displayed significantly more CD73 (a marker linked to \[strong\] TCRγδ-ligand-induced signaling; [@bib3]), than cells from the IL-17A pathway, regardless of Vγ usage ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Increased TCRγδ Signal Strength Prohibits Development of IL-17A-Secreting γδ T Cells(A) CD44/CD45RB (top) on CD24^−^ γδ T cells from E15 7-day FTOC ± GL3 (1 μg/ml). Bottom is i.c. IL-17A/IFNγ in c and d gated from top.(B) Number of CD44^hi^CD45RB^−^ (left) and CD44^+^CD45RB^+^ (right) γδ T cells in 7-day FTOCs ± GL3 described in (A).(C) Number of IL-17A^+^ CD44^hi^CD45RB^−^ γδ T cells (left) and MFI of IL-17A in these cells (right) in 7-day FTOCs ± GL3 described in (A).(D) CD44/CD45RB (top) on thymic CD24^−^ γδ T cells from neonatal (2-day-old) mice born to time-mated WT mice that received an injection of anti-CD3ε antibody (2C11; 40 μg) or PBS only (control) i.p. Bottom is i.c. IL-17A/IFNγ in c and d gated from top. Graphs show number of CD44^hi^CD45RB^−^ (top) and IL-17A^+^ CD44^hi^CD45RB^−^ (bottom) γδ T cells from neonatal mice described above.(E) CD44/CD45RB on CD24^−^ γδ T cells from E15 7-day FTOC (top) or 2-day neonatal thymus (bottom) and CD73 histograms for Vγ-specific CD44^+^CD45RB^+^ (green), CD44^hi^CD45RB^−^ (orange), or immature CD24^+^ (gray) γδ subsets. For Vγ5^+^ or Vγ6^+^ cells, gray histograms signify all CD24^+^ γδ T cells.(F) CD44/CD45RB on CD24^−^ γδ T cells from E15 7-day FTOC with MEK1/2 inhibitor UO126 (5 μM), GL3 (1 μg/ml), UO126 (5 μM) plus GL3 (1 μg/ml), or control.(G) Number of CD44^hi^CD45RB^−^ γδ T cells in (F).(H) Ratio of CD44^+^CD45RB^+^ to CD44^−^CD45RB^+^ γδ T cells in (F).Data points (B, C, G, and H) represent at least four lobes pooled. Data points (D) represent individual neonatal mice. Data are representative of at least three (A--C and F--H), two (E), or one (D) independent experiment. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001 (Student's t test or ANOVA). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

TCR signals are transduced, in part, by signals through the ERK/MAP kinase cascade ([@bib11]). Hence, to assess the consequences of weaker TCRγδ signaling, the MEK1/2 inhibitor of ERK signaling UO126 was added to 7-day E15 FTOC. Compared with control cultures, UO126 significantly increased cell number in the IL-17A-committed pathway ([Figures 4](#fig4){ref-type="fig"}F and 4G) while reducing the ratio of terminally differentiated CD44^+^CD45RB^+^ cells to less mature CD44^−^CD45RB^+^ cells in the IFNγ-committed pathway ([Figure 4](#fig4){ref-type="fig"}H). Importantly, UO126 could also rescue the number of IL-17A-committed cells in FTOC containing GL3 ([Figures 4](#fig4){ref-type="fig"}F and 4G) and improved the ratio of CD44^+^CD45RB^+^ to CD44^−^CD45RB^+^ cells ([Figure 4](#fig4){ref-type="fig"}H). Thus, manipulation of TCRγδ signal strength with either crosslinking anti-TCRγδ antibody (stronger) or an ERK pathway inhibitor (weaker) demonstrates that strong TCRγδ signals are prohibitive for the generation of γδ T cells destined to secrete IL-17A, regardless of the Vγ chain they use.

Discussion {#sec3}
==========

Here, we describe a straightforward methodology to study the sequential thymic development of murine γδ T cells. TCRδ^+^CD25^+^ cells, which are considered the earliest thymic γδ T cell subset ([@bib23], [@bib25]), begin development by downregulating CD25, followed by CD24. How this is triggered remains to be elucidated, but TCRγδ signaling was shown to be necessary to pass beyond a TCRγδ^lo^CD25^+^ stage ([@bib23]). When cultured as a population, CD24^−^ γδ thymocytes that are CD44^−^CD45RB^−^ give rise to either IL-17A-committed CD44^hi^CD45RB^−^ cells that express RORγt but not T-bet or to IFNγ-committed CD45RB^+^ cells that (more gradually) express T-bet but not RORγt. Interestingly, our CD44/CD45RB plots show overlap with CD44/Ly-6C plots suggested to identify naive-like and memory-like peripheral γδ T cell subsets ([@bib17]). Thus, combination staining of CD44 with both Ly-6C and CD45RB may prove particularly insightful.

Importantly, our analyses identify two thymic pathways of functional γδ T cell differentiation that diverge from a common CD24^−^CD44^−^CD45RB^−^ phenotype. Whether each CD24^−^CD44^−^CD45RB^−^ cell has potential to enter both pathways, or whether the subset instead contains both IL-17A- and IFNγ-committed progenitors, is still uncertain. However, that some CD24^−^CD44^−^CD45RB^−^ γδ T cells can already make either IL-17A or IFNγ (but not both) supports a model in which commitment to an IL-17A- or IFNγ-secreting fate, with initial expression of corresponding "master" transcriptional regulators ([@bib19]), spans an early window of development that includes CD24^+^ subsets. Nonetheless, commitment appears fully established by the time cells upregulate either CD44 or CD45RB from the CD24^−^CD44^−^CD45RB^−^ stage. Notably, these committed cells do not necessarily display immediate capacity to secrete cytokine. This is particularly evident for CD45RB^+^ cells in the IFNγ pathway as only a minority secrete IFNγ ex vivo. However, when isolated and cultured on OP9-DL1 cells for a further 5 days, virtually all then secrete IFNγ (but not IL-17A). These observations suggest thymic commitment of γδ progenitors to distinct effector fates is distinguishable (temporally and presumably mechanistically) from actual capacity to secrete cytokine.

The identification of surface marker-defined, cytokine secretion-independent developmental pathways for γδ T cell generation facilitated re-examination of TCRγδ signal strength requirements for thymic commitment of γδ progenitors to specific effector fates. Strong antibody-induced TCRγδ signaling favored the IFNγ pathway ([@bib13], [@bib21], [@bib25], [@bib28]). This was consistent with significantly higher expression of CD73 (recently purported to reflect increased TCRγδ signaling; [@bib3]) on cells committed to secrete IFNγ compared with those in the IL-17A pathway. Cells in the IFNγ pathway express CD45RB that is upregulated on developing Vγ5^+^Vδ1^+^ cells in the presence of Skint1 ([@bib28]), a possible ligand for the Vγ5Vδ1 TCR ([@bib1]). In the absence of Skint1, Vγ5^+^ cells instead adopt characteristics of Vγ6^+^ cells, including capacity to secrete IL-17A ([@bib28]). In our studies, strong antibody-induced TCRγδ signaling prevented the development of all cells destined for the IL-17A pathway, which included a sizable number of Vγ1^+^ and Vγ2/3^+^ cells, as well as Vγ4^+^ and Vγ6^+^ cells. This appears at odds with a recent report that revealed an absence of IL-17A-committed (but not IFNγ-committed) γδ T cells in SKG mice that have severely reduced Zap-70 activity ([@bib29]). Although interpreted as showing that strong TCRγδ signaling is required for commitment to an IL-17A-secreting fate, we instead prefer the explanation that generation of IL-17A-producing γδ T cells is simply Zap-70 (and/or Syk) dependent. Importantly however, our data show that this Zap-70 dependence cannot equate to transducing a strong TCRγδ signal.

Our results indicate that at least one downstream mediator of strong TCRγδ signaling is the ERK/MAP kinase pathway, as its inhibition promoted the IL-17A pathway while reducing progression through the IFNγ pathway. Moreover, it reversed many (but not all) effects of increased TCRγδ signal strength mediated by anti-TCRδ antibody. Thus, activation of the ERK/MAP kinase pathway by strong TCRγδ signaling is a key limiter of progression to an IL-17A-secreting fate. As mentioned above, such strong signaling may reflect engagement of TCR ligand, as supported by complete segregation, in the prenatal thymus, of Vγ5^+^ cells to the IFNγ pathway and Vγ6^+^ cells to the IL-17A pathway ([@bib1], [@bib28]). However, γδ T cells bearing Vγ1^+^, Vγ2/3^+^, or Vγ4^+^ TCRs were readily detected in both pathways. This could imply that only some of these TCRs engage ligand. Alternatively, ligand-independent signaling ([@bib18]) that depends on surface expression levels and/or features of particular Vγ regions may dictate the proportion of cells that successfully engage the ERK/MAP kinase pathway. Finally, Vγ7^+^ cells, which largely seed the murine intestine, are not present in either pathway, suggesting that factors other than TCRγδ signaling should also be considered ([@bib5]). These ideas, and the involvement of other downstream signaling cascades, are currently under investigation.

Experimental Procedures {#sec4}
=======================

Additional details are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Mice {#sec4.1}
----

C57BL/6 (B6) mice were purchased from Charles River Laboratories. All mice were fetal (E14--E17), neonatal (1--3 days), post-natal (4--8 days), or adult (8--12 weeks; female). All experiments involving animals were performed in full compliance with UK Home Office regulations and institutional guidelines.

FTOCs {#sec4.2}
-----

Thymic lobes from B6 mice were cultured on Nuclepore membrane filter discs (Whatman) in complete RPMI-1640 medium plus 10% fetal calf serum (FCS) for 7--14 days.

OP9-DL1 Co-cultures {#sec4.3}
-------------------

OP9-DL1 cells were provided by J.C. Zúniga-Pflücker (University of Toronto).

Flow Cytometry {#sec4.4}
--------------

For detection of Vγ5Vδ1 and Vγ6Vδ1, cells were pre-stained with GL3 followed by 17D1. For i.c. cytokine staining (eBioscience), cells were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma) and 1 μg/ml ionomycin (Sigma) for 4 hr at 37°C. Acquisition was performed with an LSR-II or a Canto II (BD). Analysis was performed using FlowJo (Tree Star).

Statistical Analysis {#sec4.5}
--------------------

GraphPad Prism software was used to analyze data, which are presented as mean ± SD. Two-tailed Student's unpaired t test was used when only two groups were compared, and one-way ANOVA with Tukey's test was used for multiple comparisons. Significance was determined at p ≤ 0.05.
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